Drug intelligence / Profile preview

ANT-1403

Development stage: Discontinued
Lead developer: Allergan

Overview

ANT-1403 is a biological molecule developed by Anterios (later acquired by Allergan, now part of AbbVie) for the treatment of primary axillary hyperhidrosis. It was investigated as a novel therapy for excessive underarm sweating, but its precise mechanism of action has not been defined in public sources. The drug reached phase II clinical trials before development was discontinued. Its modality is described as a biological factor or small molecule in different sources, but it is primarily referenced as a biological agent targeting skin disorders[1][2].

Other names: ANT 1403ANT1403ANT-1403

Beyond the preview

Go deeper on ANT-1403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANT-1403.

Explore the full profile